<DOC>
	<DOCNO>NCT02677311</DOCNO>
	<brief_summary>This prospective case control study . Participants enrol case subject control subject , depend upon gonadotoxicity chemoradiation therapy . The chemotherapeutic regimen determine per standard care . Participants receive GnRHa ( Lupron ) standard care menstrual suppression . Blood draw pelvic ultrasound baseline , 6 month 12 month post completion chemotherapy intervention . The duration study approximately 12 months.The study time include time necessary completion cancer treatment population , approximate 8-12 month , time allow complete excretion Lupron systemic circulation reliable test hypothalamic pituitary ovarian ( H-P-O ) axis . The result study use guide large study evaluate efficacy gonadotropin release hormone agonist ( GnRHa ) ovarian preservation therapy young subject receive chemoradiation .</brief_summary>
	<brief_title>GnRHA Therapy Ovarian Preservation Pediatric Cancer Patient</brief_title>
	<detailed_description>This study utilize survey questionnaire . Data collect via chart review direct subject and/or guardian interview . Electronic medical record access approved clinical research personnel retrieve clinical laboratory data . At initial visit , follow perform collected subject : Body Mass Index ; age thelarche ; age menarche ; Tanner stag breast pubic hair ; oncologic diagnosis ; date oncologic diagnosis ; chemoradiation therapy treatment regimen ; date initiation chemoradiation therapy ; pre-treatment ovarian function blood test ; date GnRHa therapy initiate ; pelvic ultrasound performed assess ovarian volume antral follicle count . The subject receive GnRHa 11.25 mg every 2 month completion chemotherapy , consistent current clinical care University Kentucky Medical Center ( UKMC ) . Study blood test evaluate ovarian function pelvic ultrasound perform three time point : immediately prior initiation GnRHa therapy 6 12 month chemoradiation therapy complete . The subject/guardian contact study team regular interval assess progress plan time study visit . At subsequent visit , investigator record date chemoradiation therapy treatment end ; date reason GnRHa therapy discontinue ; presence breakthrough bleeding ( BTB ) ; time BTB relation recent GnRHa injection . In order document bleeding pattern , subject ask fill pictorial assessment bleed chart every month study . Six month completion chemoradiation therapy , investigator assess post-treatment ovarian function blood test level perform pelvic U/S ass ovarian volume antral follicle count . Investigator assess resumption spontaneous menses , parity , date subject demise , applicable . Twelve month completion chemotherapy , assess post-treatment ovarian function blood test level ; perform pelvic U/S ass ovarian volume antral follicle count . Investigator assess resumption spontaneous menses , parity , date subject demise , applicable .</detailed_description>
	<criteria>Receiving chemoradiation therapy Documented ovarian function Require menstrual suppression GnRHa chemoradiation therapy Patients University Kentucky , Norton Healthcare Cincinnati Children 's Hospital Medical Center Under 8 year age old 19 year age Male Unable provide consent assent</criteria>
	<gender>Female</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>